Scarica l'app Stockscreener
0.4402
3.48%
0.0148
Dopo l'orario di chiusura:
.44
-0.0002
-0.05%
Precedente Chiudi:
$0.4254
Aprire:
$0.4679
Volume 24 ore:
30.25M
Relative Volume:
4.87
Capitalizzazione di mercato:
$148.12M
Reddito:
$52.29M
Utile/perdita netta:
$-134.84M
Rapporto P/E:
-0.5869
EPS:
-0.75
Flusso di cassa netto:
$-117.11M
1 W Prestazione:
+6.05%
1M Prestazione:
-26.39%
6M Prestazione:
-6.91%
1 anno Prestazione:
-81.35%
Intervallo 1D:
$0.421
$0.4783
Intervallo di 1 settimana:
$0.4195
$0.4783
Portata 52W:
$0.3846
$2.84
Sangamo Therapeutics Inc Stock (SGMO) Company Profile
Nome
Sangamo Therapeutics Inc
Settore
Industria
Telefono
(510) 970-6000
Indirizzo
501 CANAL BLVD., RICHMOND, CA
Confronta SGMO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SGMO
Sangamo Therapeutics Inc
|
0.4402 | 143.14M | 52.29M | -134.84M | -117.11M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.15 | 107.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
742.00 | 78.84B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.93 | 60.05B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
915.36 | 55.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
206.60 | 45.09B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-12-13 | Aggiornamento | Truist | Hold → Buy |
| 2024-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-04-28 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-02-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-01-06 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-06-13 | Ripresa | Wedbush | Neutral |
| 2021-05-04 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-01-07 | Ripresa | Guggenheim | Neutral |
| 2021-01-06 | Iniziato | Stifel | Hold |
| 2020-12-16 | Ripresa | H.C. Wainwright | Buy |
| 2020-09-08 | Iniziato | BofA Securities | Buy |
| 2020-07-07 | Iniziato | SunTrust | Buy |
| 2019-08-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2018-10-10 | Iniziato | Guggenheim | Buy |
| 2018-06-20 | Iniziato | BofA/Merrill | Buy |
| 2017-11-15 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2017-06-22 | Ripresa | Jefferies | Buy |
| 2016-11-01 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-10-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-10-23 | Ripresa | Jefferies | Buy |
| 2013-05-03 | Iniziato | BioLogic Equity Research | Sell |
| 2011-02-23 | Reiterato | JMP Securities | Mkt Outperform |
| 2010-07-29 | Reiterato | Wedbush | Outperform |
| 2009-10-19 | Iniziato | Brean Murray | Sell |
| 2009-10-07 | Reiterato | Leerink Swann | Outperform |
| 2009-08-25 | Reiterato | JMP Securities | Mkt Outperform |
Mostra tutto
Sangamo Therapeutics Inc Borsa (SGMO) Ultime notizie
Sangamo Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - MarketScreener
Sangamo Therapeutics (SGMO) Surges on FDA Fast Track Designation for ST-503 - GuruFocus
Sangamo rises as FDA grants Fast Track status to neuropathic pain asset - Seeking Alpha
Sangamo (SGMO) Gains FDA Fast Track for Chronic Pain Treatment - GuruFocus
Sangamo Therapeutics secures FDA fast track for ST-503 - Traders Union
Sangamo Therapeutics receives U.S. FDA fast track designation for ST-503 - MarketScreener
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy - The Manila Times
Sangamo Therapeutics (Nasdaq: SGMO) gets FDA Fast Track for ST-503 in small fiber neuropathy - Stock Titan
How Sangamo Therapeutics Inc. (GBY) stock performs in volatility spikesIndex Update & Proven Capital Preservation Methods - Newser
Can Sangamo Therapeutics Inc. (GBY) stock reach $200 price targetTrade Ideas & AI Powered Market Entry Ideas - Newser
Is Sangamo Therapeutics Inc. (GBY) stock a top hedge fund pick2025 Technical Patterns & High Yield Stock Recommendations - Newser
Earnings Report: Is Sangamo Therapeutics Inc. stock attractive for retirement portfolios2025 Top Gainers & Capital Efficient Trading Techniques - BỘ NỘI VỤ
Sangamo Therapeutics Q3 2025 Earnings Preview - MSN
Sangamo Therapeutics, Inc. (GBY.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
How Recent Developments Are Rewriting the Story for Sangamo Therapeutics - Yahoo Finance
[Form 4] SANGAMO THERAPEUTICS, INC Insider Trading Activity - Stock Titan
What drives Sangamo Therapeutics Inc. (GBY) stock priceCandlestick Trading Patterns & High Return Investment Ideas - earlytimes.in
Sangamo rises as FDA accepts rolling submission request for gene therapy - MSN
Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% Dive - simplywall.st
What analysts say about Sangamo Therapeutics Inc GBY stockDividend Yield Trends & The Smart Money Is Buying These Picks - earlytimes.in
Sangamo Therapeutics, Inc. (SGMO) Stock: Soars 9.95% on FDA Milestone for Gene Therapy - parameter.io
With cash running low, East Bay biotech Sangamo bets on FDA submission strategySan Francisco Business Times - The Business Journals
Sangamo Therapeutics Gets US FDA Approval to Begin Rolling BLA Submission for Fabry Gene Therapy - MarketScreener
Sangamo Therapeutics (SGMO) Advances Fabry Disease Therapy with FDA Rolling Submission - GuruFocus
Sangamo (SGMO) Advances Gene Therapy for Fabry Disease with FDA Approval Process - GuruFocus
FDA accepts Sangamo’s rolling BLA submission for Fabry disease gene therapy - Investing.com Canada
Sangamo Therapeutics announces FDA acceptance of BLA rolling submission request - MarketScreener
Sangamo Therapeutics Announces FDA Acceptance of Rolling Submission for Gene Therapy ST-920 for Fabry Disease Treatment - Quiver Quantitative
Sangamo stock climbs after FDA accepts BLA rolling submission request By Investing.com - Investing.com Canada
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease - The Manila Times
Sangamo (Nasdaq: SGMO) rolling ST-920 Fabry BLA accepted by FDA for accelerated review - Stock Titan
Will Sangamo Therapeutics Inc. (GBY) stock rise with strong economyWeekly Trend Report & Verified Technical Trade Signals - newser.com
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Will Sangamo Therapeutics Inc. (GBY) stock gain from green policiesQuarterly Investment Review & Safe Entry Trade Reports - newser.com
Sangamo Therapeutics (SGMO) Price Target Decreased by 20.73% to 3.32 - MSN
Real time pattern detection on Sangamo Therapeutics Inc. stockJuly 2025 Summary & Expert Approved Trade Ideas - newser.com
How buybacks impact Sangamo Therapeutics Inc. stock value2025 Retail Activity & Real-Time Volume Analysis - newser.com
How hedge fund analytics apply to Sangamo Therapeutics Inc. stockMarket Performance Recap & Consistent Profit Alerts - newser.com
Sangamo Therapeutics Inc. stock chart pattern explainedTrend Reversal & Reliable Trade Execution Plans - newser.com
Tick level data insight on Sangamo Therapeutics Inc. volatilityJuly 2025 Trends & Safe Investment Capital Preservation Plans - newser.com
Why analysts recommend Sangamo Therapeutics Inc. (GBY) stock2025 Year in Review & Fast Entry and Exit Trade Plans - newser.com
Sangamo Therapeutics Inc Azioni (SGMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
1.02%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):